ReviewInternational journal of molecular sciences2023
Eosinophilic Fasciitis: Current and Remaining Challenges.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Characteristics and factors associated with treatment response among patients with eosinophilic fasciitis: a systematic review and meta-analysis.Rheumatology international · 2025Pooled it
- Immune checkpoint inhibitor-induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Observational
- Article
- Idiopathic inflammatory myopathies: a comprehensive review, new concepts on diagnostic imaging and whole-body MRI.European radiology · 2026Review
- Ischemic stroke despite therapeutic anticoagulation in eosinophilic fasciitis with compartment syndrome and deep vein thrombosis: a case report.Thrombosis journal · 2026Article
- [Shulman syndrome: An atypical presentation of a rare disease].Revista medica del Instituto Mexicano del Seguro Social · 2026Article
- Case Report: Eosinophilic fasciitis with PM-Scl antibody positivity: expanding the serological spectrum.Frontiers in medicine · 2026Article
- [Eosinophilic fascitis: A case report and literature review].Revista medica del Instituto Mexicano del Seguro Social · 2026Review
- Rituximab and Intravenous Immunoglobulin (IVIG) for Refractory Eosinophilic Fasciitis: A Case Report.Clinical case reports · 2026Article
- Eosinophilic Fasciitis in a Young Adult: A Rare Presentation Potentially Triggered by the Epstein-Barr Virus.Cureus · 2025Article
- Restricted Movement Associated with Unilateral Diffuse Fasciitis.Internal medicine (Tokyo, Japan) · 2025Article
- Clinicopathological profile of eosinophilic fasciitis: a retrospective cohort study from a neuromuscular disorder center in China.Arthritis research & therapy · 2025Article
- A Modeling Study for Hip Fracture Rates in Romania.Journal of clinical medicine · 2025Article
- Overlap of generalized morphea and eosinophilic fasciitis after recreational exposure to epoxy resin.JAAD case reports · 2025Article
- Eosinophilic fasciitis following postpartum: A rare case report.The Journal of international medical research · 2025Article
- A Challenging Case of Eosinophilic Fasciitis Without Classic Histopathological Findings.The Permanente journal · 2025Article
- Recurrent Eosinophilic Fasciitis: The First Case Report.Clinical, cosmetic and investigational dermatology · 2025Article
- Eosinophilic Fasciitis: A Case Series.Cureus · 2025Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eosinophilic fasciitis (EF), defined as diffuse fasciitis with eosinophilia by Shulman in 1974, is a disease with unknown etiology and whose pathogenesis is still being researched. The diagnosis is based on the clinical aspects (skin induration with an "orange peel" appearance), the lab results (eosinophilia, increased inflammatory markers), the skin biopsy with the pathognomonic histopathological result, as well as the typical MRI changes. The treatment includes glucocorticoids and immunosuppressive drugs. Due to severe refractory cases, the treatment remains a challenge. EF is still a disease with potential for further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.